{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:29:50Z","timestamp":1794547790783,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacogenomics is rapidly transforming precision medicine, yet regulatory policies governing its implementation vary widely across countries. This review aims to provide a global perspective on pharmacogenomics guidelines, with a particular focus on high-risk drug reactions such as carbamazepine therapy-induced severe cutaneous adverse reactions. Carbamazepine was selected as a representative example due to its inclusion on the World Health Organization\u2019s essential medicines list and its well-documented association with high-risk alleles, which are linked to severe cutaneous adverse reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis\u2014conditions with significant mortality rates. Two databases, Overton and Dimensions, were searched to identify relevant national guidelines and policy documents in English. Countries were identified based on document availability and access to governmental sources. The review revealed that all examined countries recognized genetic variation in carbamazepine response within their guidelines, showing notable consistency. However, religious implications related to pharmacogenomics were largely absent. The findings also indicated a growing global momentum toward integrating pharmacogenomics into healthcare systems, although the depth and scope of regulation differ. The United States stands out for its comprehensive pharmacogenomics policy framework, which extends to clinical and industry settings. Lessons from the U.S. model can inform policy development in other regions, tailored to each country\u2019s healthcare infrastructure and cultural context. In conclusion, global harmonization of pharmacogenomics policies is essential to foster international collaboration, enable data sharing, and enhance the safe and equitable implementation of pharmacogenomics in clinical practice.<\/jats:p>","DOI":"10.1038\/s41431-025-01950-6","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T11:59:25Z","timestamp":1758715165000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4097-5577","authenticated-orcid":false,"given":"Safa","family":"Omran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Hua","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-7895","authenticated-orcid":false,"given":"Siew Li","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"1950_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jac5.1118","volume":"2","author":"JK Hicks","year":"2019","unstructured":"Hicks JK, Aquilante CL, Dunnenberger HM, Gammal RS, Funk RS, Aitken SL, et al. Precision pharmacotherapy: integrating pharmacogenomics into clinical pharmacy practice. J Am Coll Clin Pharm. 2019;2:303\u201313.","journal-title":"J Am Coll Clin Pharm"},{"key":"1950_CR2","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.sapharm.2023.07.012","volume":"19","author":"S Omran","year":"2023","unstructured":"Omran S, Leong SL, Blebil A, Mohan D, Teoh SL. Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: a systematic review. Res Soc Adm Pharm. 2023;19:1399\u2013411.","journal-title":"Res Soc Adm Pharm"},{"key":"1950_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/641089","volume":"2013","author":"YW Lam","year":"2013","unstructured":"Lam YW. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharm. 2013;2013:641089.","journal-title":"ISRN Pharm"},{"key":"1950_CR4","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.xphs.2017.04.051","volume":"106","author":"ME Klein","year":"2017","unstructured":"Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci. 2017;106:2368\u201379.","journal-title":"J Pharm Sci"},{"key":"1950_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/bcp.13828","volume":"85","author":"G Suarez-Kurtz","year":"2019","unstructured":"Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA. Conference report: pharmacogenomics in special populations at WCP2018. Br J Clin Pharm. 2019;85:467\u201375.","journal-title":"Br J Clin Pharm"},{"key":"1950_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-pharmtox-030920-025745","volume":"61","author":"W-C Chang","year":"2021","unstructured":"Chang W-C, Tanoshima R, Ross CJD, Carleton BC. Challenges and opportunities in implementing pharmacogenetic testing in clinical settings. Annu Rev Pharm Toxicol. 2021;61:65\u201384.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"1950_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cpt.1004","volume":"103","author":"EJ Phillips","year":"2018","unstructured":"Phillips EJ, Sukasem C, Whirl-Carrillo M, M\u00fcller DJ, Dunnenberger HM, Chantratita W, et al. Clinical pharmacogenetics implementation consortium guideline for HLA Genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharm Ther. 2018;103:574\u201381.","journal-title":"Clin Pharm Ther"},{"key":"1950_CR8","unstructured":"NIH. Carbamazepine Therapy and HLA Genotype 2018 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK321445\/#:~:text=DPWG%20recommendations%20include%20avoiding%20the,%3A11%20(Table%202)."},{"key":"1950_CR9","unstructured":"Neurosciences MSO. Consensus Guidelines on the Management of Epilepsy 2017 2017 Available from: https:\/\/www.neuro.org.my\/assets\/guideline\/2017Epilepsy.pdf."},{"key":"1950_CR10","unstructured":"Medscape. Carbamazepine (Rx) Medscape: WebMD LLC; 2024 Available from: https:\/\/reference.medscape.com\/drug\/tegretol-xr-equetro-carbamazepine-343005."},{"key":"1950_CR11","unstructured":"WHO. WHO Model List of Essential Medicines - 23rd list, 2023 2021 Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02."},{"key":"1950_CR12","unstructured":"WHO. Technical Advisory Group on Genomics (TAG-G): WHO; 2024 Available from: https:\/\/www.who.int\/groups\/technical-advisory-group-on-genomics-(tag-g)#:~:text=The%20Technical%20Advisory%20Group%20on,and%20technologies%20for%20global%20health."},{"key":"1950_CR13","unstructured":"CPIC. The Clinical Pharmacogenetics Implementation Consortium (CPIC\u00ae): CPIC; 2024 Available from: https:\/\/cpicpgx.org\/guidelines\/."},{"key":"1950_CR14","unstructured":"FDA. FDA and pharmacogenomics 2019 [Available from: https:\/\/cpicpgx.org\/wp-content\/uploads\/2019\/08\/fda-and-pgen-2019.pdf."},{"key":"1950_CR15","unstructured":"FDA. Clinical Laboratory Improvement Amendments (CLIA) 2023 Available from: https:\/\/www.fda.gov\/medical-devices\/ivd-regulatory-assistance\/clinical-laboratory-improvement-amendments-clia."},{"key":"1950_CR16","unstructured":"CMS_US. Pharmacogenomics Testing 2021 Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdId=39063."},{"key":"1950_CR17","unstructured":"Government_US F. The Genetic Information Nondiscrimination Act of 2008 (GINA) 2008 Available from: https:\/\/crsreports.congress.gov\/product\/pdf\/RL\/RL34584\/15#:~:text=GINA%2C%20P.L.%20110%2D233%2C,is%20not%20without%20potential%20problems."},{"key":"1950_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/ajhp\/zxab339","volume":"79","author":"CE Haidar","year":"2022","unstructured":"Haidar CE, Petry N, Oxencis C, Douglas JS, Hoffman JM. ASHP Statement on the Pharmacist\u2019s Role in Clinical Pharmacogenomics. Am J Health-Syst Pharm. 2022;79:704\u20137.","journal-title":"Am J Health-Syst Pharm"},{"key":"1950_CR19","unstructured":"NHGRI_NIH. Discipline-specific genomic competencies National Human Genome Research Institute (NHGRI) 2024 Available from: https:\/\/www.genome.gov\/For-Health-Professionals\/Provider-Genomics-Education-Resources\/Competencies."},{"key":"1950_CR20","unstructured":"Canada H. Health Canada 2024 Available from: https:\/\/www.canada.ca\/en\/health-canada.html."},{"key":"1950_CR21","unstructured":"EMA. European Medicines Agency: Guideline on good pharmacogenomic practice 2018 Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacogenomic-practice-first-version_en.pdf."},{"key":"1950_CR22","unstructured":"EMA. European Medicines Agency: Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products 2012 Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/2024-08\/guideline_on_the_use_of_methodologies_in_the_pharmacokinetic_evaluation_of_medicinal_products.pdf."},{"key":"1950_CR23","unstructured":"EMA. European Medicines Agency: Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products 2016 Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/2024-06\/guideline-key-aspects-use-pharmacogenomics-pharmacovigilance-medicinal-products-ema.pdf."},{"key":"1950_CR24","unstructured":"U-PGx. Ubiquitous Pharmacogenomics 2020 Available from: https:\/\/upgx.eu\/ubiquitous-pharmacogenomics\/."},{"key":"1950_CR25","unstructured":"DPWG. DPWG: Dutch Pharmacogenetics Working Group 2005 Available from: https:\/\/www.pharmgkb.org\/page\/dpwg."},{"key":"1950_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1189976","volume":"14","author":"D Kabbani","year":"2023","unstructured":"Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. Front Pharm. 2023;14:1189976.","journal-title":"Front Pharm"},{"key":"1950_CR27","unstructured":"RCP_BPS. Personalized prescribing: using pharmacogenomics to improve patient outcomes. 2022 Available from: https:\/\/www.bps.ac.uk\/getmedia\/b43a3dca-1bbf-4bff-9379-20bef9349a8c\/Personalised-prescribing-full-report.pdf.aspx."},{"key":"1950_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/bmj.316.7134.852","volume":"316","author":"NA Holtzman","year":"1998","unstructured":"Holtzman NA, Shapiro D. Genetic testing and public policy. Bmj. 1998;316:852\u20136.","journal-title":"Bmj"},{"key":"1950_CR29","unstructured":"UK_GOV. Genome UK: the future of healthcare 2020 [Available from: https:\/\/www.gov.uk\/government\/publications\/genome-uk-the-future-of-healthcare\/genome-uk-the-future-of-healthcare."},{"key":"1950_CR30","unstructured":"UK_GOV. Genome UK: 2022 to 2025 implementation plan for England 2022 Available from: https:\/\/www.gov.uk\/government\/publications\/genome-uk-2022-to-2025-implementation-plan-for-england\/genome-uk-2022-to-2025-implementation-plan-for-england#:~:text=The%20UK%20is%20a%20global,health%20outcomes%20at%20lower%20cost."},{"key":"1950_CR31","unstructured":"RPS. The Role of Pharmacy in Pharmacogenomics: Royal Pharmaceutical Society Position Statement 2022 Available from: https:\/\/www.rpharms.com\/development\/pharmacogenomics\/pgx-position-statement."},{"key":"1950_CR32","unstructured":"UKRI. Developing regulatory science to advance healthcare 2025 Available from: https:\/\/www.ukri.org\/news\/developing-regulatory-science-to-advance-healthcare\/."},{"key":"1950_CR33","unstructured":"Liverpool_University. New pharmacogenomics centre to help UK move towards personalised prescribing 2025 Available from: https:\/\/news.liverpool.ac.uk\/2025\/01\/28\/new-pharmacogenomics-centre-to-help-uk-move-towards-personalised-prescribing\/."},{"key":"1950_CR34","unstructured":"AUS_Genomics. Australian Genomics Health Alliance 2016 Available from: https:\/\/www.australiangenomics.org.au\/what-we-do\/."},{"key":"1950_CR35","unstructured":"AUS_GOV_Health. Australian Government Department of Health and Aged Care: National Health Genomics Policy Framework 2017 Available from: https:\/\/www.health.gov.au\/resources\/collections\/national-health-genomics-policy-framework."},{"key":"1950_CR36","unstructured":"RCPA. Royal College of Pathologists of Australasia Position Statement on the Utilisation of pharmacogenetics in healthcare 2022 Available from: https:\/\/www.rcpa.edu.au\/Library\/College-Policies\/Position-Statements\/Utilisation-of-pharmacogenetics-in-healthcare#:~:text=Pharmacogenetics%20has%20potential%20application%20in,by%20a%20different%20genetic%20pathway."},{"key":"1950_CR37","unstructured":"DH_HK. Department of Health (DH) Strategic Development of Genomic Medicine in Hong Kong (HK) 2017 Available from: https:\/\/www.healthbureau.gov.hk\/download\/press_and_publications\/otherinfo\/200300_genomic\/SCGM_report_en.pdf."},{"key":"1950_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1586\/17512433.1.4.505","volume":"1","author":"A Ishiguro","year":"2008","unstructured":"Ishiguro A, Toyoshima S, Uyama Y. Current Japanese regulatory situations of pharmacogenomics in drug administration. Expert Rev Clin Pharm. 2008;1:505\u201314.","journal-title":"Expert Rev Clin Pharm"},{"key":"1950_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-015-0033-3","volume":"9","author":"K Mitropoulos","year":"2015","unstructured":"Mitropoulos K, Al Jaibeji H, Forero DA, Laissue P, Wonkam A, Lopez-Correa C, et al. Success stories in genomic medicine from resource-limited countries. Hum Genomics. 2015;9:11.","journal-title":"Hum Genomics"},{"key":"1950_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000502916","volume":"22","author":"S Chumnumwat","year":"2019","unstructured":"Chumnumwat S, Lu ZH, Sukasem C, Winther MD, Capule FR, Abdul Hamid A, et al. Southeast asian pharmacogenomics research network (SEAPharm): current status and perspectives. Public Health Genomics. 2019;22:132\u20139.","journal-title":"Public Health Genomics"},{"key":"1950_CR41","unstructured":"HSA. Singapore Government Agency Health Sciences Authority (HSA): Recommendations for HLA-B*1502 genotype testing prior to initiation of carbamazepine in new patients 2013 Available from: https:\/\/www.hsa.gov.sg\/announcements\/safety-alert\/recommendations-for-hla-b-1502-genotype-testing-prior-to-initiation-of-carbamazepine-in-new-patients."},{"key":"1950_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/pgs-2017-0009","volume":"18","author":"HX Ang","year":"2017","unstructured":"Ang HX, Chan SL, Sani LL, Quah CB, Brunham LR, Tan BOP, et al. Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. Pharmacogenomics. 2017;18:891\u2013910.","journal-title":"Pharmacogenomics"},{"key":"1950_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-018-0420-4","volume":"11","author":"HY Chong","year":"2018","unstructured":"Chong HY, Allotey PA, Chaiyakunapruk N. Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Med Genomics. 2018;11:94.","journal-title":"BMC Med Genomics"},{"key":"1950_CR44","unstructured":"ASM. Academy of Sciences Malaysia (ASM)Position Paper on Precision Medicine Initiative in Malaysia 2019 Available from: https:\/\/www.akademisains.gov.my\/studies\/sig\/precision-medicine\/."},{"key":"1950_CR45","unstructured":"MOH_Malaysia. Ministry of Health Malaysia: Guidelines On Ethical Issues In The Provision Of Medical Genetics Services In Malaysia 2019 Available from: https:\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/Garis%20Panduan\/Garis%20panduan%20Umum%20(Awam)\/Guidelines_On_Ethical_Issues_In_The_Provision_Of_Medical_Genetics_Services_In_Malaysia_(1).pdf."},{"key":"1950_CR46","unstructured":"AAS_AESA_AUDA-NEPAD. A Framework for the Implementation of Genomic Medicine for Public Health in Africa 2021 Available from: https:\/\/openresearchafrica.org\/documents\/4-9."},{"key":"1950_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.797465","volume":"13","author":"EA El-Attar","year":"2022","unstructured":"El-Attar EA, Helmy Elkaffas RM, Aglan SA, Naga IS, Nabil A, Abdallah HY. Genomics in Egypt: Current Status and Future Aspects. Front Genet. 2022;13:797465.","journal-title":"Front Genet"},{"key":"1950_CR48","unstructured":"FDA. US FDA: Table of pharmacogenomics biomarkers in drug labels 2024 Available from: https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling."},{"key":"1950_CR49","first-page":"29","volume":"10","author":"VL Yip","year":"2017","unstructured":"Yip VL, Pirmohamed M. The HLA-A*31:01 allele: influence on carbamazepine treatment. Pharmgenomics Pers Med. 2017;10:29\u201338.","journal-title":"Pharmgenomics Pers Med"},{"key":"1950_CR50","unstructured":"BNF. British National Formulary: Carbamazepine Monograph: BNF Organization; 2022. Available from: https:\/\/nhathuocngocanh.com\/wp-content\/uploads\/2022\/05\/BNF-83-British-National-Formulary-in-2022.pdf."},{"key":"1950_CR51","unstructured":"AMH. Australian Medicines Handbook: Carbamazepine Monograph: \u00a9 Australian Medicines Handbook Pty Ltd; 2024 Available from: https:\/\/amhonline-amh-net-au.ap1.proxy.openathens.net\/chapters\/neurological-drugs\/antiepileptics\/other-antiepileptics\/carbamazepine."},{"key":"1950_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-019-0229-z","volume":"13","author":"K Krebs","year":"2019","unstructured":"Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics. 2019;13:39.","journal-title":"Hum Genomics"},{"key":"1950_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-01003-9","volume":"13","author":"AN Abou Tayoun","year":"2021","unstructured":"Abou Tayoun AN, Fakhro KA, Alsheikh-Ali A, Alkuraya FS. Genomic medicine in the Middle East. Genome Med. 2021;13:184.","journal-title":"Genome Med"},{"key":"1950_CR54","unstructured":"QPHI. Qatar Precision Health Institute (QPHI): Qatar Genome Program 2023 Available from: https:\/\/www.qatargenome.org.qa\/."},{"key":"1950_CR55","doi-asserted-by":"crossref","unstructured":"Marks ME, Botta RK, Abe R, Beachkofsky TM, Boothman I, Carleton BC, et al. Updates in SJS\/TEN: collaboration, innovation, and community. Frontiers in Medicine. 2023;10.","DOI":"10.3389\/fmed.2023.1213889"},{"key":"1950_CR56","first-page":"01","volume":"21","author":"M Khattab","year":"2023","unstructured":"Khattab M, Baguneid M, Ali BR, Sadek B, Beiram R, Atallah B, et al. A review of pharmacogenomics studies assessing the knowledge and attitudes of physicians and pharmacists across the Arab and Middle Eastern Region. Pharm Pr. 2023;21:01\u201312.","journal-title":"Pharm Pr"},{"key":"1950_CR57","unstructured":"NIH. The precision medicine initiative cohort program-building a research foundation for 21st-century medicine National Institute of Health2015 Available from: https:\/\/www.nih.gov\/sites\/default\/files\/research-training\/initiatives\/pmi\/pmi-working-group-report-20150917-2.pdf."},{"key":"1950_CR58","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2217\/pgs-2020-0056","volume":"21","author":"M Nagy","year":"2020","unstructured":"Nagy M, Attya M, Patrinos GP. Unraveling Heterogeneity of the Clinical Pharmacogenomic Guidelines in Oncology Practice Among Major Regulatory Bodies. Pharmacogenomics. 2020;21:1247\u201364.","journal-title":"Pharmacogenomics"},{"key":"1950_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/FPC.0000000000000405","volume":"30","author":"CH van der Wouden","year":"2020","unstructured":"van der Wouden CH, B\u00f6hringer S, Cecchin E, Cheung K-C, D\u00e1vila-Fajardo CL, Deneer VHM, et al. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenet Genomics. 2020;30:131\u201344.","journal-title":"Pharmacogenet Genomics"},{"key":"1950_CR60","doi-asserted-by":"crossref","unstructured":"Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al Maskari F. Genomics and pharmacogenomics knowledge, attitude and practice of pharmacists working in United Arab Emirates: findings from focus group discussions-A qualitative study. J Pers Med. 2020;10:1\u201312.","DOI":"10.3390\/jpm10030134"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01950-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01950-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01950-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:09:49Z","timestamp":1768810189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01950-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01950-6","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the work reported herein did not require ethics approval because it did not involve animal or human participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}